vida: extract claims from 2026-05-07-psychopharmacology-institute-q1-2026-glp1-review

- Source: inbox/queue/2026-05-07-psychopharmacology-institute-q1-2026-glp1-review.md
- Domain: health
- Claims: 2, Entities: 0
- Enrichments: 2
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/fda-2026-cds-enforcement-discretion-expands-to-single-recommendation-ai-without-defining-clinical-appropriateness.md

@@ -10,18 +10,16 @@ agent: vida
 scope: structural
 sourcer: "Covington & Burling LLP"
 related_claims: ["[[healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software]]", "[[human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs]]"]
-related:
-- FDA's 2026 CDS guidance treats automation bias as a transparency problem solvable by showing clinicians the underlying logic despite research evidence that physicians defer to AI outputs even when reasoning is visible and reviewable
-- Clinical AI deregulation is occurring during active harm accumulation not after evidence of safety as demonstrated by simultaneous FDA enforcement discretion expansion and ECRI top hazard designation in January 2026
-- FDA transparency requirements treat clinician ability to understand AI logic as sufficient oversight but automation bias research shows trained physicians defer to flawed AI even when they can understand its reasoning
-- State clinical AI disclosure laws fill a federal regulatory gap created by FDA enforcement discretion expansion because California Colorado and Utah enacted patient notification requirements while FDA's January 2026 CDS guidance expanded enforcement discretion without adding disclosure mandates
-reweave_edges:
-- FDA's 2026 CDS guidance treats automation bias as a transparency problem solvable by showing clinicians the underlying logic despite research evidence that physicians defer to AI outputs even when reasoning is visible and reviewable|related|2026-04-03
-- Clinical AI deregulation is occurring during active harm accumulation not after evidence of safety as demonstrated by simultaneous FDA enforcement discretion expansion and ECRI top hazard designation in January 2026|related|2026-04-04
-- FDA transparency requirements treat clinician ability to understand AI logic as sufficient oversight but automation bias research shows trained physicians defer to flawed AI even when they can understand its reasoning|related|2026-04-07
-- State clinical AI disclosure laws fill a federal regulatory gap created by FDA enforcement discretion expansion because California Colorado and Utah enacted patient notification requirements while FDA's January 2026 CDS guidance expanded enforcement discretion without adding disclosure mandates|related|2026-04-17
+related: ["FDA's 2026 CDS guidance treats automation bias as a transparency problem solvable by showing clinicians the underlying logic despite research evidence that physicians defer to AI outputs even when reasoning is visible and reviewable", "Clinical AI deregulation is occurring during active harm accumulation not after evidence of safety as demonstrated by simultaneous FDA enforcement discretion expansion and ECRI top hazard designation in January 2026", "FDA transparency requirements treat clinician ability to understand AI logic as sufficient oversight but automation bias research shows trained physicians defer to flawed AI even when they can understand its reasoning", "State clinical AI disclosure laws fill a federal regulatory gap created by FDA enforcement discretion expansion because California Colorado and Utah enacted patient notification requirements while FDA's January 2026 CDS guidance expanded enforcement discretion without adding disclosure mandates", "fda-2026-cds-enforcement-discretion-expands-to-single-recommendation-ai-without-defining-clinical-appropriateness", "fda-transparency-requirements-treat-clinician-understanding-as-sufficient-oversight-despite-automation-bias-evidence", "regulatory-deregulation-occurring-during-active-harm-accumulation-not-after-safety-evidence", "state-clinical-ai-disclosure-laws-fill-federal-regulatory-gap-created-by-fda-enforcement-discretion-expansion", "fda-treats-automation-bias-as-transparency-problem-contradicting-evidence-that-visibility-does-not-prevent-deference"]
+reweave_edges: ["FDA's 2026 CDS guidance treats automation bias as a transparency problem solvable by showing clinicians the underlying logic despite research evidence that physicians defer to AI outputs even when reasoning is visible and reviewable|related|2026-04-03", "Clinical AI deregulation is occurring during active harm accumulation not after evidence of safety as demonstrated by simultaneous FDA enforcement discretion expansion and ECRI top hazard designation in January 2026|related|2026-04-04", "FDA transparency requirements treat clinician ability to understand AI logic as sufficient oversight but automation bias research shows trained physicians defer to flawed AI even when they can understand its reasoning|related|2026-04-07", "State clinical AI disclosure laws fill a federal regulatory gap created by FDA enforcement discretion expansion because California Colorado and Utah enacted patient notification requirements while FDA's January 2026 CDS guidance expanded enforcement discretion without adding disclosure mandates|related|2026-04-17"]
 ---
 
 # FDA's 2026 CDS guidance expands enforcement discretion to cover AI tools providing single clinically appropriate recommendations while leaving clinical appropriateness undefined and requiring no bias evaluation or post-market surveillance
 
-FDA's revised CDS guidance introduces enforcement discretion for CDS tools that provide a single output where 'only one recommendation is clinically appropriate' — explicitly including AI and generative AI. Covington notes this 'covers the vast majority of AI-enabled clinical decision support tools operating in practice.' The critical regulatory gap: FDA explicitly declined to define how developers should evaluate when a single recommendation is 'clinically appropriate,' leaving this determination entirely to the entities with the most commercial interest in expanding the carveout's scope. The guidance excludes only three categories from enforcement discretion: time-sensitive risk predictions, clinical image analysis, and outputs relying on unverifiable data sources. Everything else — ambient AI scribes generating recommendations, clinical chatbots, drug dosing tools, differential diagnosis generators — falls under enforcement discretion. No prospective safety monitoring, bias evaluation, or adverse event reporting specific to AI contributions is required. Developers self-certify clinical appropriateness with no external validation. This represents regulatory abdication for the highest-volume AI deployment category, not regulatory simplification.
+FDA's revised CDS guidance introduces enforcement discretion for CDS tools that provide a single output where 'only one recommendation is clinically appropriate' — explicitly including AI and generative AI. Covington notes this 'covers the vast majority of AI-enabled clinical decision support tools operating in practice.' The critical regulatory gap: FDA explicitly declined to define how developers should evaluate when a single recommendation is 'clinically appropriate,' leaving this determination entirely to the entities with the most commercial interest in expanding the carveout's scope. The guidance excludes only three categories from enforcement discretion: time-sensitive risk predictions, clinical image analysis, and outputs relying on unverifiable data sources. Everything else — ambient AI scribes generating recommendations, clinical chatbots, drug dosing tools, differential diagnosis generators — falls under enforcement discretion. No prospective safety monitoring, bias evaluation, or adverse event reporting specific to AI contributions is required. Developers self-certify clinical appropriateness with no external validation. This represents regulatory abdication for the highest-volume AI deployment category, not regulatory simplification.
+
+## Supporting Evidence
+
+**Source:** Psychopharmacology Institute Q1 2026 Review, FDA suicidality warning removal
+
+FDA removed suicidal ideation and behavior warning from GLP-1 RA labeling in January 2026 after comprehensive review found no increased risk. The warning was carried over from older weight-loss medications without GLP-1-specific data. This represents FDA acting on evidence review to remove unwarranted warnings, contrasting with enforcement discretion expansion for AI where safety evidence is accumulating but oversight is decreasing.

domains/health/glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring.md

@@ -31,3 +31,10 @@ The Psychopharmacology Institute — a CME platform for practicing psychiatrists
 **Source:** Dr. Will Sauvé, Osmind CMO
 
 Osmind CMO Dr. Sauvé frames competency gap as existential for psychiatry: 'If our field of psychiatry does not get a hundred percent ahead of how this GLP thing works, then we're going to be left behind.' Identifies specific gap: psychiatrists managing GLP-1-prescribed patients without understanding central mechanisms, dosing nuances, or psychiatric side effects.
+
+
+## Extending Evidence
+
+**Source:** Psychopharmacology Institute Q1 2026 Review
+
+Psychopharmacology Institute Q1 2026 guidance specifies monthly monitoring using validated depression/suicidality tools and psychoeducation protocols for patients/caregivers, but this guidance reaches only CME-engaged psychiatrists, not primary care prescribers who write majority of psychiatric medications. The Institute recommends HbA1c screening at 5.4% for schizophrenia patients on clozapine/olanzapine—a specific, actionable threshold that primary care lacks access to without CME engagement.

domains/health/glp1-psychiatric-guidance-prioritizes-antipsychotic-metabolic-side-effects-over-primary-psychiatric-indications.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: Q1 2026 psychiatric clinical guidance frames GLP-1 as a tool for managing clozapine/olanzapine metabolic side effects rather than treating psychiatric conditions directly, despite emerging evidence for mood and addiction applications
+confidence: experimental
+source: Psychopharmacology Institute Q1 2026 Review
+created: 2026-05-07
+title: GLP-1 psychiatric guidance prioritizes antipsychotic metabolic side-effect management over primary psychiatric indications, reflecting conservative professional society positioning
+agent: vida
+sourced_from: health/2026-05-07-psychopharmacology-institute-q1-2026-glp1-review.md
+scope: functional
+sourcer: Psychopharmacology Institute
+challenges: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation"]
+related: ["semaglutide-reduces-psychiatric-worsening-42-percent-within-individual-design", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-eating-disorder-screening-protocol-scoff-plus-history-plus-behavioral-assessment-recommended-for-pre-treatment-risk-stratification", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required"]
+---
+
+# GLP-1 psychiatric guidance prioritizes antipsychotic metabolic side-effect management over primary psychiatric indications, reflecting conservative professional society positioning
+
+The Psychopharmacology Institute's Q1 2026 guidance identifies schizophrenia patients on clozapine or olanzapine as the priority population for GLP-1 use—specifically those 'who cannot easily switch treatment.' The clinical framing is narrow: GLP-1 addresses metabolic risk (weight gain, metabolic syndrome) while patients remain on necessary antipsychotics. The guidance recommends HbA1c screening at 5.4% (below the 5.7% prediabetes threshold) for early-stage metabolic risk targeting. This is a preventative, side-effect management application, not a primary psychiatric treatment. Notably absent: any guidance on GLP-1 for substance use disorders despite JAMA Psychiatry RCT evidence on alcohol use disorder being available by Q1 2026. The Institute's framing is 'manage metabolic side effects of antipsychotics using GLP-1' rather than 'GLP-1 is a psychiatric drug.' This conservative positioning contrasts with Osmind's broader 'GLP-1 as psychiatric medication' narrative and suggests professional societies are lagging clinical evidence by ~1 year. The prioritization of metabolic side-effect management over primary psychiatric indications reflects institutional caution about expanding GLP-1's psychiatric role beyond well-established safety profiles in metabolic populations.

domains/health/psychiatry-addresses-glp1-competency-through-cme-not-formal-guidelines-creating-uneven-distribution.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: Professional society guidance for psychiatric GLP-1 use is delivered through continuing medical education platforms rather than formal clinical practice guidelines, leaving competency gaps in primary care and non-CME-engaged prescribers
+confidence: experimental
+source: Psychopharmacology Institute Q1 2026 Review
+created: 2026-05-07
+title: Psychiatry addresses GLP-1 prescribing competency through CME infrastructure rather than formal APA guidelines, creating uneven competency distribution across the prescriber population
+agent: vida
+sourced_from: health/2026-05-07-psychopharmacology-institute-q1-2026-glp1-review.md
+scope: structural
+sourcer: Psychopharmacology Institute
+supports: ["the-mental-health-supply-gap-is-widening-not-closing"]
+related: ["the-mental-health-supply-gap-is-widening-not-closing", "glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "who-glp1-guideline-omits-eating-disorder-screening-despite-pharmacovigilance-signal", "glp1-eating-disorder-screening-protocol-scoff-plus-history-plus-behavioral-assessment-recommended-for-pre-treatment-risk-stratification", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations"]
+---
+
+# Psychiatry addresses GLP-1 prescribing competency through CME infrastructure rather than formal APA guidelines, creating uneven competency distribution across the prescriber population
+
+As of Q1 2026, no formal American Psychiatric Association clinical practice guideline exists for GLP-1 use in psychiatric populations. Instead, the Psychopharmacology Institute—a widely used CME platform—serves as the de facto guidance infrastructure. The Institute's Q1 2026 review provides structured clinical protocols including: (1) metabolic screening with HbA1c cutoff of 5.4% for schizophrenia patients on clozapine/olanzapine, (2) monthly monitoring using validated depression/suicidality tools, and (3) psychoeducation protocols for patients and caregivers. This guidance reaches psychiatrists who actively engage with CME platforms but creates systematic gaps: primary care prescribers who write the majority of psychiatric medications lack access to this guidance infrastructure, and psychiatrists who don't use CME platforms remain unaware of monitoring protocols. The Institute's guidance notably excludes substance use disorder applications despite JAMA Psychiatry RCT evidence being available by Q1 2026, demonstrating ~1 year evidence-to-practice lag even within the CME channel. The structural reliance on CME rather than formal guidelines means competency distribution follows professional development engagement rather than prescribing authority, creating a mismatch between who prescribes and who has training.

inbox/archive/health/2026-05-07-psychopharmacology-institute-q1-2026-glp1-review.md

@@ -7,10 +7,13 @@ date: 2026-04-01
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-07
 priority: high
 tags: [glp-1, psychiatry, clinical-guidance, CME, schizophrenia, monitoring, suicidality]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content